Kiniksa Pharmaceuticals Files 8-K on Operations

Ticker: KNSA · Form: 8-K · Filed: 2025-07-29T00:00:00.000Z

Sentiment: neutral

Topics: operations, financials, reporting

TL;DR

Kiniksa Pharma dropped an 8-K, expect an update on financials soon.

AI Summary

Kiniksa Pharmaceuticals International, plc filed an 8-K on July 29, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.

Why It Matters

This 8-K filing signals that Kiniksa Pharmaceuticals is providing updated information regarding its financial performance and condition to the SEC and its investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting operational and financial information, without immediate news of significant events like mergers or major setbacks.

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

The provided text of the 8-K filing indicates it is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not include the specific financial figures within this excerpt.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on July 29, 2025.

What is the principal executive office address for Kiniksa Pharmaceuticals International, plc?

The principal executive office is located at 23 Old Bond Street, Floor 3, London, W1S 4PZ, England, United Kingdom.

What is the SEC file number for Kiniksa Pharmaceuticals International, plc?

The SEC file number for Kiniksa Pharmaceuticals International, plc is 001-730430.

What is the Standard Industrial Classification (SIC) code for Kiniksa Pharmaceuticals International, plc?

The Standard Industrial Classification code for Kiniksa Pharmaceuticals International, plc is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001104659-25-071413.txt : 20250729 0001104659-25-071413.hdr.sgml : 20250729 20250729073042 ACCESSION NUMBER: 0001104659-25-071413 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250729 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250729 DATE AS OF CHANGE: 20250729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 251157562 BUSINESS ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ BUSINESS PHONE: 7814319100 MAIL ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ FORMER COMPANY: FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. DATE OF NAME CHANGE: 20180205 8-K 1 tm2521890d1_8k.htm FORM 8-K false 0001730430 0001730430 2025-07-29 2025-07-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): July 29, 2025   Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter)   England and Wales   001-730430   98-1795578 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.)   23 Old Bond Street, Floor 3 London , W1S 4PZ England , United Kingdom (Address of principal executive offices, including zip code)   ( 781 ) 431-9100 (Registrant’s telephone number, including area code)   N/A (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Class A Ordinary Shares, $0.000273235 nominal value   KNSA   The Nasdaq Stock Market LLC         (Nasdaq Global Select Market)   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨           Item 2.02. Results of Operations and Financial Condition.     On July 29, 2025, Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of the press release is furnished with this Current Report on Form 8-K

View on Read The Filing